Using a blinded semi-quantitative light microscopic scoring method, we further determined that MAL2 expression was significantly down regulated in the majority of samples examined (in 61–65% of the total cases examined) from all three carcinoma types displaying 2- to 3-fold decreases in immunolabeling (Figure 1B). Here, MAL2 is linked to carcinoma.